1Spencer FA, Allegrone J, Goldberg RJ, et al. Association of statin therapy with outcomes of acute coronary syndrome: The GRACE study. Ann Intern Med, 2004,140:857-866.
2Kinlay S, Schiwartz GG, Olsson AG, et al. High-dose atorvastatin enhances the delince in inflammatory markers in patients with acute coronary syndrome in the MIRACL study. Circulation, 2003, 108:1560-1566.
3Cannon CP, Braunwald E, MoCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndrome. N Eng J Med, 2004, 350:1495-1504.
4De Lemons JA, Blazing MA, Wiviott SD, et al. for the A to Z Investigators early intensive vs a delayed conservative simvatatin strategy with acute coronary syndromes: phase Z of the A to Z trial. JAMA, 2004, 292:1307-1316.
5Grundy SM, Cleeman JI, Merz NB, et al. Implications of recent clinical trials for the national cholesterol education program adult treatment panel Ⅲ guidelines. Circulation, 2004,110:227-239.
2kinlay s, chiwartz gg, olsson ag, et al. High-dose atorvastatin enhances the delince in inflammatory markers in patients with acute coronary syndrome in the miracle study. Circulation,2003,108:1560-1566.
3cannon cp, braunwald e, mocabe ch, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndrome. N eng j med,2004,350:1495-1504.
4de lemons ja, blazing ma, wiviott sd, et al. For the a to z investigators early intensive vs a delayed conservative simvatatin strategy with acute coronary syndrome: phase z of the a to z trail. Jama,2004,292:1307-1316.
